(Image: National Human Genome Research Institute) Antibodies are Y-shaped molecules composed of four polypeptide chains: two identical heavy chains and two identical light chains. These chains are ...
However, currently available technologies to produce these two-for-one therapeutics rely on mutating the structure of the original antibody to promote heterodimerization—a process that can ...
into a native human antibody structure. In collaboration with TG Therapeutics, Light Chain has brought one internally developed κλ body, TG-1801 (formerly NI-1701), into clinical trials for ...
and much more simply structured than the antibodies in our own blood. That size and structure means they can be "redesigned" in the lab. Professor James Naismith, director of the Rosalind Franklin ...